Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression

被引:103
作者
Hirshberg, B
Rother, KI
Digon, BJ
Lee, J
Gaglia, JL
Hines, K
Read, EJ
Chang, R
Wood, BJ
Harlan, DM
机构
[1] NIDDK, Transplantat & Autoimmun Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[2] NIH, Ctr Clin, Dept Transfus Med, US Dept HHS, Bethesda, MD 20892 USA
[3] NIH, Special Procedures Diagnost Radiol Dept, Dept Transfus Med, US Dept HHS, Bethesda, MD 20892 USA
关键词
D O I
10.2337/diacare.26.12.3288
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - The aim of this study was to describe the National Institutes of Health's experience initiating an islet isolation and transplantation center, including descriptions of our first six recipients, and lessons learned. RESEARCH DESIGN AND METHODS - Six females with chronic type 1 diabetes, hypoglycemia unawareness, and no endogenous insulin secretion (undetectable serum C-peptide) were transplanted with allogenic islets procured from brain dead donors. To prevent islet rejection, patients received daclizumab, sirolimus, and tacrolimus. RESULTS - All patients noted less frequent and less severe hypoglycemia and one-half were, insulin independent at 1 year. Serum C-peptide persists in all but one patient (follow-up 17-22 months), indicating continued islet function. Two major procedure-related complications occurred: partial portal vein thrombosis and intra-abdomin. at hemorrhage. While we observed no cytomegalovirus infection or malignancy, recipients frequently developed transient mouth ulcers, diarrhea, edema, hypercholesterolemia, weight loss, myelosuppression, and other symptoms. Three patients discontinued immunosuppressive therapy: two because of intolerable toxicity (deteriorating kidney function and sirolimus-induced pneumonitis) while having evidence for continued islet function (one was insulin independent) and one because of gradually disappearing islet function. CONCLUSIONS - We established an islet isolation and transplantation program and achieved a 50% insulin-independence rate after at most two islet infusions. Our experience demonstrates that centers not previously engaged in islet transplantation can initiate a program, and our data and literature analysis support not only the promise of islet transplantation but also its remaining hurdles which include the limited islet supply, procedure-associated complications, imperfect immunosuppressive regimens, suboptimal glycemia control, and toss of function over time.
引用
收藏
页码:3288 / 3295
页数:8
相关论文
共 31 条
  • [1] Hypoglycemia in the diabetes control and complications trial
    不详
    [J]. DIABETES, 1997, 46 (02) : 271 - 286
  • [2] Intrathoracic organ transplantation in the United Kingdom 1995-99: results from the UK cardiothoracic transplant audit
    Anyanwu, AC
    Rogers, CA
    Murday, AJ
    [J]. HEART, 2002, 87 (05) : 449 - 454
  • [3] BALLINGER WF, 1972, SURGERY, V72, P175
  • [4] Brendel M, 1999, INT ISLET TRANSPLANT, P1
  • [5] Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management
    Bretzel, RG
    Brandhorst, D
    Brandhorst, H
    Eckhard, M
    Ernst, W
    Freimann, S
    Rau, W
    Weimar, B
    Rauber, K
    Hering, BJ
    Brendel, MD
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (01): : 140 - 143
  • [6] Portal venous pressure changes after sequential clinical islet transplantation
    Casey, JJ
    Lakey, JRT
    Ryan, EA
    Paty, BW
    Owen, R
    O'Kelly, K
    Nanji, S
    Rajotte, RV
    Korbutt, GS
    Bigam, D
    Kneteman, NN
    Shapiro, AMJ
    [J]. TRANSPLANTATION, 2002, 74 (07) : 913 - 915
  • [7] Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratifred by heart failure severity
    Deng, MC
    De Meester, JMJ
    Smits, JMA
    Heinecke, J
    Scheld, HH
    [J]. BRITISH MEDICAL JOURNAL, 2000, 321 (7260) : 540 - 545
  • [9] THE QUALITY OF LIFE OF PATIENTS WITH END-STAGE RENAL-DISEASE
    EVANS, RW
    MANNINEN, DL
    GARRISON, LP
    HART, LG
    BLAGG, CR
    GUTMAN, RA
    HULL, AR
    LOWRIE, EG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (09) : 553 - 559
  • [10] Rapamycin: Clinical results and future opportunities
    Kahan, BD
    Camardo, JS
    [J]. TRANSPLANTATION, 2001, 72 (07) : 1181 - 1193